Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 20
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Vox Sang ; 119(1): 62-69, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-37920933

RESUMEN

BACKGROUND AND OBJECTIVES: Granulocyte transfusion (GTX) is a treatment option for severe infections in patients with neutropenia. In previous studies, hydroxyethyl starch (HES) was used to enhance red blood cell sedimentation for granulocyte collection (GC). However, there are safety concerns about HES, and HES is not readily available in some countries. Therefore, we compared the granulocyte counts and GC efficiency achieved by two apheresis systems without HES. MATERIALS AND METHODS: All consecutive GC procedures performed between July 2011 and March 2018 at our hospital were analysed. COBE Spectra was used until 5 February 2016, and Spectra Optia was used afterwards. HES was not used. RESULTS: Twenty-six GC procedures were performed, including 18 performed using COBE Spectra and 8 using Spectra Optia. When Spectra Optia was used, >1 × 1010 neutrophils were collected from seven of the eight (88%) procedures. Although there was no significant difference in the granulocyte yield between COBE Spectra-based and Spectra Optia-based GC procedures, the collection efficiency of Spectra Optia was significantly higher than that of COBE Spectra (p = 0.021). Furthermore, the granulocyte yields of Spectra Optia-based GC tended to be more strongly correlated with the peripheral blood neutrophil count on the day of apheresis than those of COBE Spectra-based GC. CONCLUSION: Our results suggest that Spectra Optia achieves greater GC efficiency than COBE Spectra, even without HES. GTX may be a therapeutic option for severe neutropenia, even in places where HES is not available.


Asunto(s)
Eliminación de Componentes Sanguíneos , Neutropenia , Humanos , Eliminación de Componentes Sanguíneos/métodos , Granulocitos , Movilización de Célula Madre Hematopoyética , Almidón
3.
Acta Haematol ; 127(3): 186-8, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22353685

RESUMEN

Primary anaplastic large cell lymphoma (ALCL) of skeletal muscle is very rare. We report a case of ALCL arising from the left psoas muscle. A 14-year-old girl presented with a large left inguinal tumor. She complained of a 2-month history of left leg pain, which had been exacerbated upon leg extension, and she had become aware of a rapidly growing left inguinal tumor 3 weeks before admission. CT scan and MRI revealed a large tumor arising from the left major psoas muscle and protruding into the inguinal region. In view of the tumor's location and the patient's age, soft tissue tumors such as rhabdomyosarcoma and primitive neuroectodermal tumor were initially considered. However, histopathological examination yielded a diagnosis of anaplastic lymphoma kinase-positive ALCL. The serum level of soluble interleukin-2 receptor was markedly elevated at 50,414 U/ml, and this also strongly suggested ALCL. Although rarely reported, ALCL is an important entity to consider in the differential diagnosis of skeletal muscle tumors in children and young adults.


Asunto(s)
Linfoma Anaplásico de Células Grandes/diagnóstico , Neoplasias de los Músculos/diagnóstico , Músculos Psoas/patología , Adolescente , Cromosomas Humanos Par 2 , Cromosomas Humanos Par 5 , Diagnóstico Diferencial , Femenino , Humanos , Linfoma Anaplásico de Células Grandes/diagnóstico por imagen , Linfoma Anaplásico de Células Grandes/patología , Imagen por Resonancia Magnética , Neoplasias de los Músculos/diagnóstico por imagen , Neoplasias de los Músculos/patología , Cintigrafía , Tomografía Computarizada por Rayos X , Translocación Genética
4.
Pediatr Hematol Oncol ; 29(1): 99-103, 2012 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22304016

RESUMEN

The authors report the clinical course of a 3-year-old boy with stage 4 neuroblastoma (NB) complicated by hemophagocytic lymphohistiocytosis (HLH) immediately after the start of chemotherapy. The NB responded very well to the chemotherapy, but the patient developed high fever on the 2nd day, and was diagnosed as having HLH of the 7th day of chemotherapy. No infections were demonstrated, and massive tumor cell destruction resulting from the rapid effect of chemotherapy was thought to be a cause of systemic cytokine response, resulting in HLH. Methylprednisolone pulse therapy was effective for the HLH, which did not recur thereafter. HLH should be recognized as a serious adverse event during chemotherapy for advanced NB that has a large malignant cell load.


Asunto(s)
Antiinflamatorios/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Linfohistiocitosis Hemofagocítica/inducido químicamente , Linfohistiocitosis Hemofagocítica/tratamiento farmacológico , Metilprednisolona/administración & dosificación , Neuroblastoma/tratamiento farmacológico , Síndrome de Lisis Tumoral/tratamiento farmacológico , Síndrome de Lisis Tumoral/etiología , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Preescolar , Humanos , Linfohistiocitosis Hemofagocítica/patología , Masculino , Neuroblastoma/patología
5.
Acta Haematol ; 123(3): 186-90, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20224272

RESUMEN

OBJECTIVE: This study examined whether genetic polymorphisms in cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), a negative regulator of T cells, are associated with infection-associated hemophagocytic lymphohistiocytosis (IHLH) in Japanese children. METHODS: We investigated the alleles of four polymorphisms in the CTLA-4 gene [-318CT, +49AG, CT60 and a dinucleotide repeat length polymorphism (AT)n] in 43 Japanese children with IHLH and 100 healthy Japanese controls. The hyper-polymorphic (AT)n alleles were divided into two types; the shortest allele (designated as AT(7)) and the longer alleles (designated as AT(>)(7)). RESULTS: A significant difference in the distribution of the (AT)n genotype was found between patients and controls (p = 0.028). Also, the frequency of the AT(>)(7) allele was significantly higher in the patients with IHLH than in the controls (p = 0.007). No significant linkage disequilibrium was found between each polymorphism. With regard to laboratory data, patients homozygous for the CTLA-4 AT(>)(7) allele showed significantly higher serum levels of lactate dehydrogenase and soluble interleukin-2 receptor than patients with the other alleles. CONCLUSION: These results suggest that CTLA-4 polymorphisms might play a role in the development of IHLH in Japanese children.


Asunto(s)
Antígenos CD/genética , Predisposición Genética a la Enfermedad , Infecciones/complicaciones , Linfohistiocitosis Hemofagocítica/genética , Polimorfismo Genético , Adolescente , Alelos , Antígeno CTLA-4 , Niño , Preescolar , Pruebas Inmunológicas de Citotoxicidad , Femenino , Genotipo , Humanos , Lactante , Infecciones/microbiología , Infecciones/virología , Japón , Lactato Deshidrogenasas/sangre , Linfohistiocitosis Hemofagocítica/sangre , Linfohistiocitosis Hemofagocítica/complicaciones , Masculino , Receptores de Interleucina-2/sangre , Estadística como Asunto
6.
Case Rep Oncol ; 13(3): 1513-1519, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33564292

RESUMEN

A huge abdominal cystic lesion with ascites was detected in a male neonate at 31 weeks of gestation. Increasing ascites and the appearance of subcutaneous edema were detected, which caused fetal hydrops. The patient was delivered by emergency cesarean section at 33 weeks of gestation. The birth weight was 2,407 g, and the Apgar score was 8/9 points (1-/5-min values). Breathing at birth was stable, but the patient presented with remarkable abdominal distention due to the ascites. Later, the patient presented with tachypnea, and breathing gradually worsened, so an emergency operation was performed. There were no intraoperative findings within the small intestine, but there was a large amount of ascites and a cystic mass arising from the liver. The patient's breathing and circulation dynamics could only be stabilized by ascites removal, so only a tumor biopsy was performed. The pathological findings led to the diagnosis of an inflammatory myofibroblastic tumor, and steroids were administered early after surgery for the purpose of an anti-inflammatory effect and tumor shrinkage. The abdominal distention was alleviated, and blood examinations showed a reduced inflammatory response. There was no apparent shrinkage of the tumor, however; thus, radical surgical treatment was performed on day 24. The postoperative course was uneventful, so the patient was discharged on day 36. Seven years after the operation there has been no recurrence or distant metastasis.

7.
J Blood Med ; 10: 301-306, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31695540

RESUMEN

PURPOSE: Hemophagocytic lymphohistiocytosis (HLH) is a potentially lethal hyperinflammatory disorder. For further understanding of the pathogenesis of HLH, we examined serum levels of high mobility group box protein 1 (HMGB1) in children with HLH. PATIENTS AND METHODS: Serum HMGB1 levels were measured in 28 patients with HLH and 6 normal controls using a quantitative enzyme-linked immunosorbent assay. The patients were 21 boys and 7 girls, aged from 10 days to 21 years, with a median age of 8.5 years. The underlying conditions of HLH were infection-associated HLH in 18 patients, malignancy-associated HLH in 7 patients, and genetic HLH in 3 patients. The relations between serum HMGB1 levels and clinical symptoms and laboratory parameters were analyzed. RESULTS: Serum HMGB1 levels were significantly higher in patients with HLH than in normal controls (median, 6.5 ng/mL, interquartile range, 4.25-13.1). The serial serum HMGB1 levels in one patient fell to reflect the disease activity. Serum HMGB1 levels were significantly higher in patients with disseminated intravascular coagulation (DIC) than in patients without DIC (p<0.001) and were also significantly higher in patients with central nervous system (CNS) complications than in patients without CNS complications (p<0.01). Serum HMGB1 levels were positively correlated with aspartate aminotransferase (rs =0.48, p<0.01, Spearman's rank correlation coefficient) and negatively correlated with fibrinogen (rs = -0.475, p=0.011) and hemoglobin (rs = -0.465, p=0.013). CONCLUSION: Serum HMGB1 levels reflect clinical features of childhood HLH. HMGB1 is a potential mediator involved in the pathogenesis and determining the clinical findings of HLH.

8.
Pediatr Int ; 50(4): 432-5, 2008 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-18937751

RESUMEN

BACKGROUND: Mycoplasma pneumoniae has been reported to be an etiologic pathogen of infection-associated hemophagocytic lymphohistiocytosis (HLH), but few case reports have been available to date. METHODS: The clinical features of four childhood cases of M. pneumoniae-associated hemophagocytic lymphohistiocytosis (Mp-HLH) were retrospectively assessed to obtain data that might be useful for early diagnosis and effective management. The previous English-language literature pertaining to Mp-HLH was also reviewed. RESULTS: The patients were two boys and two girls, aged between 1 and 11 years of age. One patient was demonstrated to have concurrent infection with rubella. All the patients had typical radiographic features of M. pneumoniae pneumonia, and one patient also had encephalopathy as a complication. All the children underwent bone marrow examination because of antibiotic-refractory fever, mild hepatosplenomegaly, cytopenia, hyperferritinemia and elevated levels of urine beta2-microglobulin. Cytopenia and hepatosplenomegaly in the present patients were relatively mild as compared to those in cases of other infection-associated HLH such as Epstein-Barr virus infection-associated HLH. Treatment with corticosteroids resulted in prompt and complete resolution in two cases, and i.v. high-dose gammaglobulin therapy achieved a complete response in another child. Spontaneous resolution under treatment with antibiotics alone was observed in one case. CONCLUSION: Although Mp-HLH is a rare complication of M. pneumoniae infection, it should always be considered in patients with antibiotic-refractory M. pneumoniae infections with cytopenia. Mp-HLH might be effectively treated by corticosteroids or high-dose gammaglobulin. To clarify the diverse clinical manifestations of M. pneumoniae infections, immunological interactions between M. pneumoniae and the host immune system should be further investigated.


Asunto(s)
Linfohistiocitosis Hemofagocítica/etiología , Neumonía por Mycoplasma/complicaciones , Niño , Preescolar , Femenino , Humanos , Lactante , Linfohistiocitosis Hemofagocítica/diagnóstico , Masculino , Neumonía por Mycoplasma/diagnóstico , Estudios Retrospectivos
9.
Case Rep Oncol ; 11(1): 63-67, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29515412

RESUMEN

Acute lymphoblastic leukemia (ALL) presenting as Fanconi syndrome (FS) is extremely rare. Here, we report a case of ALL presenting as bilateral nephromegaly following FS. A 2-year-old girl was unexpectedly diagnosed with bilateral nephromegaly. After 2 weeks, she developed general fatigue, thirst, and polyuria. Laboratory examinations revealed renal tubular acidosis, hypokalemia, hypophosphatemia, and aminoaciduria, and FS was diagnosed. Replacement of bicarbonate and potassium did not improve her condition. Two weeks after the onset of FS, leukemic cells appeared on a peripheral blood smear, and the patient was diagnosed with precursor B-cell ALL presenting as nephromegaly and FS. Chemotherapy brought about a prompt resolution of acidosis and electrolyte abnormalities, without renal dysfunction. The patient remains well 4 years after the onset of the disease. Although extremely rare, FS should be recognized as one of the emerging renal complications of ALL.

10.
Case Rep Oncol ; 10(2): 564-570, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28868013

RESUMEN

Pulmonary vein leiomyosarcoma is extremely rare and has a poor prognosis. Surgical resection with a wide margin seems to offer the only chance of cure. The role of adjuvant therapy is controversial, and the exact efficacy of chemotherapy has not been observed. In this report, we present an 18-year-old male patient with pulmonary vein leiomyosarcoma in whom the use of paclitaxel (PAX) proved to be effective. Because the tumor originated from the left superior pulmonary vein and diffused into the left atrial wall and the junction of the right superior pulmonary vein and left atrium, the en bloc excision of the tumor was impossible. The first-line chemotherapy, including ifosfamide, doxorubicin, and dacarbazine, in conjugation with radiation therapy could not demonstrate any effect on the tumor size. However, the following PAX-containing regimen provided complete regression of the tumor. After PAX-based high-dose chemotherapy with autologous peripheral blood stem cell transplantation, the patient showed complete remission for 2 years. Although he suffered metastatic recurrences and died 4 years after the onset of symptoms, our patient's clinical course clearly reveals the efficacy of PAX.

12.
Case Rep Hematol ; 2015: 610581, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26229698

RESUMEN

Neonatal acute megakaryoblastic leukemia (AMKL) without Down syndrome (DS) is an extremely rare disorder. We report of a one-day-old male infant without DS who developed AMKL with leukemia cutis and right facial nerve palsy. Magnetic resonance imaging of the patient's brain revealed multiple intracranial tumors. A biopsy specimen of the skin lesion was suggestive of AMKL, but the bone marrow leukemic cells were less than 5% of the marrow nucleated cells. The skin and intracranial lesions had spontaneously regressed within one and a half months, but the patient's anemia and thrombocytopenia gradually worsened and the leukemic cells in the bone marrow gradually increased to more than 20% of the nucleated cells. In addition, multiple intracranial lesions reappeared at 72 days of life. We diagnosed the patient with AMKL, and chemotherapy followed by unrelated cord blood transplantation after a reduced-intensity conditioning regimen resulted in sustained complete remission. At present, the patient is well, and he has demonstrated normal development for five years.

15.
Acta Haematol ; 113(2): 124-9, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-15802891

RESUMEN

Macrophage activation syndrome (MAS) is a life-threatening complication in children with rheumatic diseases, particularly systemic-onset juvenile chronic arthritis (SOJCA). Because of the potential fatality of this condition, prompt recognition and immediate therapeutic intervention are important. This study assessed the clinical features of nine MAS events in five children with SOJCA. Nonremitting fever and decreased platelet and white blood cell counts led to a diagnosis of MAS. The urinary beta2-microglobulin (beta2MG) level was a sensitive indicator of MAS. Serum levels of beta2MG and soluble interleukin-2 receptor were also elevated. These biologic markers reflecting hyperactivated cellular immunity are useful indicators of MAS. Four children treated with cyclosporin A (CSP) achieved rapid and complete recovery, but one patient without CSP died due to rapidly progressive respiratory failure. All children treated with CSP responded quickly, and fever abated within 36 h of initiation of treatment. CSP should be added to first-line therapy of MAS.


Asunto(s)
Artritis Juvenil/complicaciones , Activación de Macrófagos , Receptores de Interleucina-2/sangre , Microglobulina beta-2/sangre , Microglobulina beta-2/orina , Adolescente , Artritis Juvenil/sangre , Artritis Juvenil/orina , Biomarcadores/sangre , Biomarcadores/orina , Niño , Preescolar , Ciclosporina/administración & dosificación , Femenino , Humanos , Inmunosupresores/administración & dosificación , Lactante , Infusiones Intravenosas , Recuento de Leucocitos , Activación de Macrófagos/efectos de los fármacos , Masculino , Recuento de Plaquetas , Síndrome
16.
Pediatr Transplant ; 9(3): 342-5, 2005 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15910392

RESUMEN

The prognosis of patients with relapsed osteosarcoma is dismal despite the use of intensive chemotherapy. We describe a patient with refractory osteosarcoma who underwent non-myeloablative peripheral blood stem cell transplantation (PBSCT) from an human leukocyte antigen (HLA)-identical sibling during a third complete remission. The patient suffered pulmonary relapse after the transplantation. Cyclosporin A withdrawal induced a graft-vs.-osteosarcoma effect and graft-vs.-host disease, but eventually the tumor progressed. Although our experience in this case suggested the presence of a graft-vs.-osteosarcoma effect during non-myeloablative allogenic PBSCT, this strategy might have limited value for refractory osteosarcoma with rapid growth kinetics.


Asunto(s)
Neoplasias Óseas/cirugía , Osteosarcoma/cirugía , Adolescente , Neoplasias Óseas/tratamiento farmacológico , Neoplasias Óseas/patología , Enfermedad Crónica , Progresión de la Enfermedad , Resultado Fatal , Enfermedad Injerto contra Huésped , Humanos , Neoplasias Pulmonares/secundario , Masculino , Osteosarcoma/tratamiento farmacológico , Osteosarcoma/patología , Trasplante de Células Madre de Sangre Periférica/métodos , Insuficiencia del Tratamiento
17.
Pediatr Int ; 47(3): 292-5, 2005 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15910453

RESUMEN

BACKGROUND: Recently a high prevalence of Helicobacter pylori infection has been reported in adult patients with chronic idiopathic thrombocytopenic purpura (cITP). Furthermore, after H. pylori eradication therapy in such patients, their platelet counts have been observed to increase, suggesting that H. pylori may be a causative agent of adult cITP. However, there have been only a few reports of children with cITP. The purpose of the present paper was to examine the association between H. pylori infection and cITP in Japanese children. METHODS: Helicobacter pylori stool antigens (HpSA) were measured and the prevalence of H. pylori infection was determined in 10 children with cITP. RESULTS: Helicobacter pylori infection was found in only two of the subjects. In a boy, the urea breath test (UBT) was also positive and the patient received eradication therapy using amoxicillin, clarithromycin, and lansoprazole for 1 week. The therapy was successful and the patient's platelet count increased. The response was maintained throughout more than 1 year of follow up. CONCLUSIONS: The prevalence of H. pylori infection in children with cITP is not high. However, the platelet count increased after eradication therapy in a boy with cITP. It is suggested that the eradication of H. pylori infection would be valuable in children, as well as in adults, with cITP.


Asunto(s)
Infecciones por Helicobacter/complicaciones , Helicobacter pylori , Púrpura Trombocitopénica Idiopática/complicaciones , Adulto , Pruebas Respiratorias , Niño , Preescolar , Enfermedad Crónica , Femenino , Estudios de Seguimiento , Infecciones por Helicobacter/diagnóstico , Infecciones por Helicobacter/epidemiología , Humanos , Masculino , Recuento de Plaquetas , Prevalencia , Púrpura Trombocitopénica Idiopática/epidemiología , Factores de Tiempo , Urea
18.
Acta Haematol ; 112(3): 160-3, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15345899

RESUMEN

Among the hematological malignancies, hypercalcemia has often been reported in lymphoid malignancies such as multiple myeloma and adult T cell leukemia/lymphoma, but it has only rarely been described in acute nonlymphocytic leukemia. We describe here a 14-month-old girl with acute monocytic leukemia complicated by severe hypercalcemia (4.6 mmol/l) at presentation. A bone survey showed generalized bone resorption, but no localized osteolytic lesions. A search for the etiology of the hypercalcemia revealed that the serum levels of parathyroid hormone-related protein (PTHrP) and also proinflammatory cytokines with stimulatory effects on osteolytic bone resorption - TNF-alpha, IL-6 and M-CSF - were elevated. The patient achieved complete remission with induction chemotherapy, and the levels of PTHrP and the cytokines became normalized. In this case, PTHrP and cytokines might have acted cooperatively to exacerbate bone resorption, resulting in severe hypercalcemia.


Asunto(s)
Hipercalcemia/etiología , Interleucina-6/sangre , Leucemia Mieloide Aguda/complicaciones , Proteína Relacionada con la Hormona Paratiroidea/sangre , Resorción Ósea/sangre , Resorción Ósea/diagnóstico por imagen , Resorción Ósea/etiología , Femenino , Humanos , Hipercalcemia/sangre , Hipercalcemia/diagnóstico por imagen , Lactante , Leucemia Mieloide Aguda/sangre , Factor Estimulante de Colonias de Macrófagos/sangre , Radiografía , Factor de Necrosis Tumoral alfa/metabolismo
19.
Pediatr Transplant ; 7(5): 400-3, 2003 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-14738303

RESUMEN

We describe a 4-yr-old boy with an occult primitive neuroectodermal tumor, who suffered fatal PTE after a second course of HDC with autologous PBSCT. On day + 52 after a second PBSCT, he was admitted because of respiratory distress. Respiratory failure rapidly progressed and he died within 4 days. The diagnosis of PTE was confirmed by a lung perfusion study with technetium-99m macroaggregated albumin, but too late to allow treatment. Although rare, PTE must be recognized as an important differential diagnosis when respiratory symptoms are observed after HDC with PBSCT.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias Encefálicas/cirugía , Tumores Neuroectodérmicos Primitivos/cirugía , Trasplante de Células Madre de Sangre Periférica/efectos adversos , Embolia Pulmonar/etiología , Neoplasias Encefálicas/complicaciones , Preescolar , Cisplatino/administración & dosificación , Cisplatino/uso terapéutico , Ciclofosfamida/administración & dosificación , Ciclofosfamida/uso terapéutico , Etopósido/administración & dosificación , Etopósido/uso terapéutico , Resultado Fatal , Humanos , Ifosfamida/administración & dosificación , Ifosfamida/uso terapéutico , Masculino , Tumores Neuroectodérmicos Primitivos/complicaciones , Embolia Pulmonar/mortalidad , Trasplante Autólogo/efectos adversos , Vincristina/administración & dosificación , Vincristina/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA